3-amino-5-anilino-1,2,4-triazole-2-carboxylic acid phenylamide | 324074-15-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-amino-5-anilino-1,2,4-triazole-2-carboxylic acid phenylamide
• 英文别名: 5-Amino-n-phenyl-3-(phenylamino)-1h-1,2,4-triazole-1-carboxamide；5-amino-3-anilino-N-phenyl-1,2,4-triazole-1-carboxamide
• CAS: 324074-15-9
• 化学式: C₁₅H₁₄N₆O
• 分子量: 294.316
• InChiKey: KNUBLBZSYZLDJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.9
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
  申请人：——

  公开号：US20040186159A1

  公开（公告）日：2004-09-23

  The use of inhibitors of GSK-3 useful for treating glaucoma is disclosed.

  抑制GSK-3用于治疗青光眼的方法被揭示。
• Triazole derivatives useful as Axl inhibitors
  申请人：Singh Rajinder

  公开号：US20070213375A1

  公开（公告）日：2007-09-13

  Triazole derivatives and pharmaceutical compositions containing the derivatives are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the derivatives in treating diseases or conditions associated with Axl catalytic activity are also disclosed.

  本发明揭示了三唑衍生物及含有该衍生物的制药组合物，其在抑制受体蛋白酪氨酸激酶Axl的活性方面具有有用性。本发明还揭示了使用该衍生物治疗与Axl催化活性相关的疾病或病况的方法。
• Substituted triazole diamine derivatives as kinase inhibitors
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1712550A2

  公开（公告）日：2006-10-18

  Use of substituted triazole diamine derivatives in the manufacture of a medicament for the treatment of a kinase mediated disorder wherein the disorder is mediated by the selective inhibition of at least one kinase selected from cyclin dependent kinase and a tyrosine kinase.

  使用取代的三唑二胺衍生物制造治疗激酶介导的疾病的药物，其中该疾病是通过选择性抑制至少一种选自细胞周期蛋白依赖性激酶和酪氨酸激酶的激酶而介导的。
• Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomatous optic neuropathy
  申请人：Alcon, Inc.

  公开号：EP2281560A1

  公开（公告）日：2011-02-09

  The use of inhibitors of GSK-3 useful for treating, preventing or inhibiting glaucoma, including treating glaucomatous optic neuropathy, is disclosed.

  本研究公开了用于治疗、预防或抑制青光眼（包括治疗青光眼性视神经病变）的 GSK-3 抑制剂的用途。
• DIAMINO-1,2,4-TRIAZOLE-CARBOXYLIC ACID DERIVATIVES AS GSK-3 INHIBITORS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1200415A1

  公开（公告）日：2002-05-02